$1.3 billion CAD market cap is quite conservative in my opinion if top line is positive. Look at how market caps have moved with positive and negative CVOT trial top lines run by the big pharmas (i.e. drugs for CETP, PCSK9, SGLT2, GLP1-R agonists). If we sail smoothly through SSRA and hit the mark with top line, then the floor is double your estimate in my opinion. Then if the full data set doesn't reveal any surprises and we don't hit any snags with FDA or EMA with the drug applications, then the climb is even higher.